Esketamine Therapy
Esketamine Therapy is a pharmacotherapeutic intervention that belongs to the class of glutamatergic rapid-acting antidepressant treatments, distinguished by its administration of the S-enantiomer of ketamine as a nasal spray formulation to alleviate treatment-resistant depression in conjunction with an oral antidepressant.
223
Publications
14.7K
Citations
1.2K
Authors
480
Institutions
Publications per year
2017–2026
219
Parents
223
Vanina Popova, Ella Daly, Madhukar H. Trivedi et al. · American Journal of Psychiatry · 2019 · 872 citations · Full text
Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin et al. · American Journal of Psychiatry · 2018 · 665 citations · Full text
Maggie Fedgchin, Madhukar H. Trivedi, Ella Daly et al. · The International Journal of Neuropsychopharmacology · 2019 · 590 citations · Full text
1–5 of 223
1.2K
23
h-index
19
h-index
18
h-index
17
h-index
14
h-index
1–5 of 1.2K
480
Janssen (United States)
Hopewell, United States
28 h-index
290 publications
53.4K citations

Janssen (Belgium)
Beerse, Belgium
21 h-index
69 publications
17.4K citations
Yale University
New Haven, United States
13 h-index
17 publications
2.4K citations
Janssen Scientific Affairs (United States)
Titusville, United States
12 h-index
41 publications
1.1K citations

Universidade Federal de São Paulo
São Paulo, Brazil
11 h-index
81 publications
3.5K citations
First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
9 h-index
41 publications
2.4K citations

Università Cattolica del Sacro Cuore
Milan, Italy
8 h-index
27 publications
802 citations
The University of Texas Southwestern Medical Center
Dallas, United States
8 h-index
10 publications
1.6K citations
1–8 of 480
15 publications · 824 citations
13
h-index
14 publications · 378 citations
13
h-index
9 publications · 548 citations
9
h-index
9 publications · 284 citations
9
h-index
7 publications · 261 citations
7
h-index
1–5